An analysis in head and neck squamous cell carcinoma, no predictive value for FcγRIIIa F158V polymorphism was detected for cetuximab efficacy24; and a study in refractory mCRC patients treated with anti-EGFR antibodies did not found significant associations between FcγRIIIa polymorphism and clinical outcome15. Here, FCGR3A is linked to head and neck squamous cell carcinoma.